|By PR Newswire||
|March 28, 2014 10:04 AM EDT||
DUBLIN, Mar. 28, 2014 /PRNewswire/ --
Research and Markets
) has announced the addition of the
report to their offering.
As the air becomes more contaminated, incidence of asthma and chronic obstructive pulmonary diseases also increases. Consequently, more market space is provided for relevant drug manufacturers.
Asthma is a common multiple disease mainly caused by inheritance and environment factors. Recurrent attacks of asthma can lead to complications such as chronic obstructive pulmonary disease, emphysema, cor pulmonale, heart failure and respiratory failure. Sometimes it can endanger patients' lives.
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease that is not fully reversible. It includes chronic bronchitis and emphysema. Pathogens include smoking, air pollution, small airway infection and pneumoconiosis. There are approximately 600 million people worldwide suffering from chronic obstructive pulmonary diseases. According to WHO, COPD is the fourth biggest killer among diseases worldwide. It ranks the same with AIDS after heart diseases, cerebrovascular diseases and acute pulmonary infection. There are over 200 million COPD patients in the world now, and its mortality rate continues to rise year after year. More than 3 million people die of this disease every year with 1.2 million of them in China.
As patients of asthma and chronic obstructive pulmonary disease become more, demand of the medication worldwide also grows steeply. Developed by Boehringer Ingelheim Group with the trade name ""Spiriva"", tiotropium bromide was approved in the Netherlands and Philippines for the first time in June 2002. It was approved to China in 2006. Global sales revenue of Spiriva in 2012 was USD 4.71 billion, increased by 13% YOY.
According to CRI's market investigation, the CAGR of sales revenue of tiotropium bromide in China sample hospital market is more than 70% from 2007 to 2012. Most market share was seized by Boehringer Ingelheim Group followed by Chia Tai Tianqing Pharmaceutical, which totally added up to over 90% of the market. Besides Spiriva from Boehringer Ingelheim Group, four Chinese pharmaceutical manufacturers have received production approval.
Industrial development and lack of environmental concern have led to serious air contamination in China. Incidence of COPD in China is predicted to keep increasing, leading to increasing demand of relevant medication. Anticipation shows that market size of tiotropium bromide in China will keep expanding rapidly in the next few years.
Key Topics Covered:
1 Relevant Concepts of Tiotropium Bromide
2 Market Overview of Tiotropium Bromide in China, 2009-2013
3 Investigation on Sales Value of Tiotropium Bromide in China, 2009-2013
4 Investigation on Market Share of Major Tiotropium Bromide Manufacturers in China, 2009-2013
5 Investigation on Market Size of Tiotropium Bromide by Dosage Form in China, 2009-2013
6 Reference Price of Tiotropium Bromide Produced by Different Enterprises in China Hospital Market
7 Major Manufacturing Enterprises in China Tiotropium Bromide Market, 2009-2014
8 Prospect of China Tiotropium Bromide Market, 2014-2018
- Boehringer Ingelheim
- Chia Tai Tianqing Pharmaceutical Group
- Zhejiang Xianju Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/8gxjqj/investigation
Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
"We are a well-established player in the application life cycle management market and we also have a very strong version control product," stated Flint Brenton, CEO of CollabNet,, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 23, 2016 05:30 PM EDT Reads: 1,702
"We provide DevOps solutions. We also partner with some key players in the DevOps space and we use the technology that we partner with to engineer custom solutions for different organizations," stated Himanshu Chhetri, CTO of Addteq, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 23, 2016 05:30 PM EDT Reads: 1,518
In his session at @DevOpsSummit at 19th Cloud Expo, Yoseph Reuveni, Director of Software Engineering at Jet.com, will discuss Jet.com's journey into containerizing Microsoft-based technologies like C# and F# into Docker. He will talk about lessons learned and challenges faced, the Mono framework tryout and how they deployed everything into Azure cloud. Yoseph Reuveni is a technology leader with unique experience developing and running high throughput (over 1M tps) distributed systems with extre...
Jul. 23, 2016 05:30 PM EDT Reads: 1,952
Jul. 23, 2016 05:15 PM EDT Reads: 634
Jul. 23, 2016 05:00 PM EDT Reads: 924
Jul. 23, 2016 05:00 PM EDT Reads: 1,778
Jul. 23, 2016 04:45 PM EDT Reads: 888
Jul. 23, 2016 04:30 PM EDT Reads: 662
Jul. 23, 2016 04:00 PM EDT Reads: 1,801
Jul. 23, 2016 04:00 PM EDT Reads: 1,963
Jul. 23, 2016 04:00 PM EDT Reads: 2,292
Jul. 23, 2016 03:45 PM EDT Reads: 1,490
Jul. 23, 2016 03:30 PM EDT Reads: 1,828
Jul. 23, 2016 03:15 PM EDT Reads: 784
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, discussed how a cloud designed for production operations not only helps accelerate developer in...
Jul. 23, 2016 03:00 PM EDT Reads: 1,178